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Nonsteroidal Anti-Inflammatory Drugs Are an Important Cause of Acute Kidney Injury in 
Children 
Jason M. Misurac, Chad A. Knoderer, Jeffrey D. Leiser, Corina Nailescu, Amy C. Wilson, and 
Sharon P. Andreoli 
 
Objective  
 
To characterize nonsteroidal anti-inflammatory drug (NSAID)-associated acute kidney injury (AKI) in 
children. 
Study design                                                                                                                                   
We conducted a retrospective chart review of children diagnosed with AKI through the use of 
International Classification of Diseases, Ninth Revision diagnosis code 584.5 or 584.9 from January 1999 
to June 2010. Medical records were reviewed to confirm the diagnosis of AKI and to quantify NSAID 
administration. Pediatric RIFLE criteria were used to codify AKI. Patients were not classified as having 
NSAID-associated AKI if they had a diagnosis explaining AKI or comorbid clinical conditions 
predisposing to AKI development. 
Results Patients                                                                                                                        
(N = 1015) were identified through International Classification of Diseases, Ninth Revision screening. 
Twenty-one children had clinical, laboratory, and radiographic studies suggesting NSAID-associated 
acute tubular necrosis and 6 had findings suggesting NSAID-associated acute interstitial nephritis, 
representing 2.7% (27 of 1015) of the total cohort with AKI and 6.6% when excluding complex patients 
with multifactorial AKI. Children with NSAID-associated AKI had a median (range) age of 14.7 years 
(0.5-17.7 years); 4 patients (15%) were <5 years old. Fifteen of 20 children (75%) for whom dosing data 
were available received NSAIDs within recommended dosing limits. Patients <5 years old were more 
likely to require dialysis (100% vs 0%, P < .001), intensive care unit admission (75% vs 9%, P = .013), 
and a longer length of stay (median 10 vs 7 days, P = .037). 
Conclusions                                                                                                                                                 
NSAID-associated AKI accounted for 2.7% of AKI in this pediatric population. AKI typically occurred 
after the administration of correctly dosed NSAIDs. Young children with NSAID-associated AKI may 
have increased disease severity. 
Acute kidney injury (AKI) is common in hospitalized children, and its cause in hospitalized 
children is frequently multifactorial. When a patient has decreased kidney perfusion secondary to 
decreased blood volume or to decreased effective circulating blood volume, kidney perfusion is 
maintained in part by the intrarenal generation of prostacyclin.
1
 Nonsteroidal anti-inflammatory 
drugs (NSAIDs) inhibit cyclooxygenases I and II, decreasing the production of prostaglandins.
2
 
There is little evidence that NSAIDs decrease renal blood flow in the setting of normal effective 
circulating volume.
3
 However, when true or effective circulating volume is decreased, NSAIDs 
decrease renal blood flow through blockade of prostaglandin-mediated vasodilation of the 
preglomerular (afferent) arteriole.
2
 This can result in unopposed preglomerular arteriole 
constriction via the actions of endogenous catecholamines and other vasoactive compounds.
3
 
This can lead to decreased glomerular filtration rate (GFR), decreased natriuresis, and as a 
consequence of the combined effect of NSAIDs and diminished effective circulating volume, can 
ultimately result in renal ischemia and acute tubular necrosis (ATN).
1
 
NSAIDs are common analgesics and antipyretics. Indomethacin, when administered for patent 
ductus arteriosus closure, results in adverse renal side effects in as many as 40% of neonates.
4
 
However, little data are available on NSAID-associated AKI in older children. 
Preventing AKI, when possible, should be a goal of clinicians. NSAIDs are perhaps the most 
common avoidable AKI risk to which children are regularly exposed. This underscores the 
importance of understanding the natural history of NSAID-associated AKI, including the 
potential for development of chronic kidney disease. 
We sought to characterize NSAID-associated AKI in children through a retrospective chart 
review of patients at a tertiary care children's hospital. We hypothesized that volume depletion 
and/or supratherapeutic dosing of NSAIDs would be associated with increased severity of 
NSAID-associated AKI. 
Methods  
We screened all patients hospitalized at Riley Hospital for Children at Indiana University Health 
from January 1999 to June 30, 2010, identifying those who had a recorded International 
Classification of Diseases, Ninth Revision code for AKI (584.5 or 584.9). All patients 18 years 
and younger diagnosed with AKI were eligible for inclusion. Medical records were reviewed to 
confirm the diagnosis of AKI and to quantify NSAIDs administered before diagnosis. 
Patients were not classified as having NSAID-associated AKI if they received other known 
nephrotoxins or if they had comorbid clinical conditions or diseases predisposing to AKI (eg, 
complex congenital heart disease, malignancy, sickle cell disease). Patients were also excluded 
from the case definition of NSAID-associated AKI if they had a clear alternate diagnosis 
explaining their AKI (eg, hemolytic uremic syndrome, transplant rejection, or acute 
glomerulonephritis). Neonates receiving indomethacin for patent ductus arteriosus closure were 
not included. Records of patients were reviewed to determine the general distribution of AKI at 
our institution. 
Although volume depletion is an independent risk factor for AKI, patients with a history of 
volume depletion in the absence of sepsis or multiorgan failure were not excluded from 
classification as having NSAID-associated AKI, as it is likely that volume depletion increases 
the risk of NSAID use leading to AKI. 
Patient demographics, NSAID administration history, clinical and laboratory markers consistent 
with AKI, and treatment data were collected and reviewed. Cost data were obtained from 
hospital and nephrology physician reimbursement records. Billing and reimbursement data from 
intensivists, surgeons, and other consultants were not available. The NSAID dose was 
determined from the medical records as reported by the parents and/or the patient. For in-hospital 
dosing, NSAID doses were obtained from inpatient medication administration records. 
Appropriate weight-based dosage range for each patient was determined based on dose 
recommendations in Lexicomp,
5
 a commonly used medical reference tool in our institution. We 
performed further analysis of dosing based on adjusted ideal body weight,
6
 because several of 
our patients were obese. 
AKI was defined as a serum creatinine above age- and sex-related normal values and an 
estimated GFR (eGFR) <75 mL/min/1.73 m
2
.
7, 8 and 9
 The Pediatric RIFLE eGFR criteria
10
 were 
used to stage the level of AKI. Decline of renal function was measured by comparing baseline 
eGFR with eGFR nadir (eGFR calculated using peak serum creatinine level). This was used to 
allow quantitative comparisons between patients. Although equations estimating GFR are 
accurate only in the steady state, comparison of eGFR nadir with baseline eGFR has been 
previously validated as a measure of severity of kidney injury, most notably in development of 
the RIFLE and pediatric RIFLE criteria. When baseline creatinine measurement was not 
available, a baseline eGFR of 100 mL/min/1.73 m
2
 was assumed for purposes of pediatric RIFLE 
classification.
10
 
Estimates of volume depletion were obtained from the medical records as reported by the parents 
and/or the patient. Anuria was defined as no urine output for >24 hours, and oliguria was defined 
by urine output of <1 mL/kg/h for 24 hours in infants, <0.5 mL/kg/h in children <35 kg, or ≤400 
mL in 24 hours for patients >35 kg. Urine output data were used to describe AKI, not for AKI 
classification. 
Analyses 
In our laboratory, an enzymatic assay for measuring serum creatinine calibrated to reference 
measurements by isotope dilution mass spectrometry (IDMS) was implemented on December 6, 
2008. Before this, the Jaffe assay was used. The new method of creatinine measurement yields 
more precise and accurate results, but the absolute values are lower than those obtained with the 
Jaffe assay. To account for this, the updated equation for eGFR determination proposed by 
Schwartz et al
9
 was used for samples processed on or after this date, and the original equations 
proposed by Schwartz et al
7 and 8
 were used for samples processed earlier. 
Of note, pediatric RIFLE used the original Schwartz equation in its analysis of AKI. The original 
Schwartz equations can be problematic to use with data from IDMS-traceable creatinine assays 
because they can yield significant overestimations of GFR. Because pediatric RIFLE primarily 
considers percent change in eGFR in codifying AKI severity, its use is still valid with the 
updated Schwartz eGFR calculations as long as the same version of the estimating equation is 
used for each patient. In addition, overestimation of GFR by using the original Schwartz 
equations on new IDMS-traceable data would underestimate the actual degree of renal 
impairment experienced by our patients. 
Statistical analysis was performed with independent-samples t test, Fisher exact test, and Mann-
Whitney U test. The study was approved by the Indiana University-Purdue University-
Indianapolis institutional review board. 
 
Results 
One thousand fifteen patients were identified through initial International Classification of 
Diseases, Ninth Revision screening. Twenty-seven (2.7%) of the cohort were identified to have 
NSAID-associated AKI. Six hundred seven patients had comorbid conditions and multifactorial 
AKI. When excluding these children with multifactorial causes of AKI, the incidence of NSAID-
associated AKI was 6.6%. Two hundred thirty-three patients had an alternate cause of AKI (eg, 
obstruction, hemolytic-uremic syndrome, glomerulonephritis). One hundred twenty-seven 
children had AKI due to an isolated hypoxic, ischemic, or non-NSAID nephrotoxic insult; 21 
children had unexplained ATN or acute interstitial nephritis (AIN) without an hypoxic or 
nephrotoxic insult (Figure). 
 
Figure 1 Classification of patients with AKI. ∗Malignancy, complex congenital heart disease, sickle cell disease, etc. 
†Obstruction, hemolytic uremic syndrome, pyelonephritis, sepsis, transplant rejection, or glomerulonephritis. 
 
Of those patients with NSAID-associated AKI (n = 27), 21 children (78%) presented with 
clinical, laboratory, radiographic, and/or pathologic studies suggesting NSAID-associated ATN 
and 6 (22%) with clinical, laboratory, radiographic, and pathologic studies suggesting NSAID-
associated AIN. 
Demographic and clinical characteristics of the population are presented in Table I. By pediatric 
RIFLE criteria at time of peak creatinine, 2 patients (7%) were classified as having kidney injury 
(eGFR decrease of 50%-74%), and the remaining 25 patients (93%) were classified as having 
renal failure by pediatric RIFLE (eGFR decrease of ≥75% or eGFR <35 mL/min/1.73 m2).10 
Oliguria or anuria was observed in 6 of 23 patients for whom at least 24 hours of urine output 
data were available (26%). 
  
 
 
Eighteen patients (67%) had a history of volume depletion. eGFR nadir was compared between 
patients reporting volume depletion and patients for whom volume depletion was not reported. 
Median eGFR nadir was 12.3 mL/min/1.73 m
2
 (range 6.2-36.9 mL/min/1.73 m
2
) in patients 
reporting volume depletion and 23.2 mL/min/1.73 m
2
 (range 8.4-48.9 mL/min/1.73 m
2
) in 
patients not reporting any signs or symptoms of volume depletion (P = .076). 
The most commonly documented presenting complaints were vomiting (20 patients, 74%), 
abdominal pain (18 patients, 67%), and decreased urine output (15 patients, 56%); further details 
are presented in Table II. Twenty-one patients (78%) had been using NSAIDs for <7 days, 2 
patients (7%) had been using it between 7 days and 4 months, and 2 patients (7%) had been 
using it for an unspecified chronic duration. Dosage history for NSAID administration was 
available in only 20 patients. Fifteen (75%) of the patients received NSAIDs in accordance with 
recommended dosing. Two patients (10%) received over twice the recommended single dose, 
and 3 patients (15%) received a dose that was <25% above the recommended upper limit. eGFR 
nadir was calculated and compared between groups receiving appropriate and supratherapeutic 
Table I.
        Demographic and clinical characteristics of patients with NSAID-associated AKI (n = 27)
Age, y* 14.7 (0.5-17.7)
Weight, kg† 63.9 (8.3-154.2, SD 37.3)
Age- and sex-specific body mass index percentile 83 (6.8-99.9)
Male patient, No. 12 (44%)
White,  No. 24 (89%)
NSAID used,  No.
 Ibuprofen 18 (67%)
 Naproxen 3 (11%)
 Ketorolac 2 (7%)
 Ibuprofen and naproxen 2 (7%)
 Ibuprofen and ketorolac 2 (7%)
History of volume depletion, No. 18 (67%)
History of decreased urine output,  No. 15 (56%)
Duration of NSAID use, d* 4 (1-729)
History of exceeding recommended dose§ 25% (5 of 20)
Median eGFR at presentation,  mL/min/1.73 m^2* 21 (7-65)
Length of stay,  d* 8 (1-24)
Patients requiring ICU stay, No. 5 (18%)
Patients requiring dialysis, No. 4 (15%)
Time to recovery of GFR >75 mL/min/1.73 m2, d* 15 (1-180)
ICU, intensive care unit 
∗Data reported as median (range). 
†Data reported as mean (range, SD). 
‡Length versus weight percentile if age <2 years. 
§Dose information unavailable for remaining 7 patients. 
 
dosing. Median eGFR nadir was 23.2 mL/min/1.73 m
2
 (range 7.8-36.9 mL/min/1.73 m
2
) in 
patients receiving appropriate dosing and 13.1 mL/min/1.73 m
2
 (range 7.1-48.9 mL/min/1.73 m
2
) 
in patients receiving supratherapeutic dosing (P = .497). 
Because 12 of the 27 patients (44%) were at or greater than the 95th percentile for body mass 
index or weight:length, we examined dose per adjusted ideal body weight to assess whether 
obese patients had received doses appropriate for their actual weight but inappropriate for their 
adjusted ideal body weight.
6
 Based on this analysis, 2 additional patients were classified in the 
“mild overdose” range (<25% above recommended upper dosing limit). However, even in this 
analysis, 13 of the 20 (65%) for whom dosage history was available received NSAIDs within 
recommended dosing limits. 
AIN as diagnosed on the basis of biopsy and clinical course was seen in 6 patients. Treatment for 
AIN was pulse methylprednisolone followed by oral steroids in 4 of 6 patients. In 1 patient, a 
lower dose of methylprednisolone was chosen and was not followed by oral steroids. In 1 
patient, no steroids were given. 
Unexpectedly, we found that patients <5 years of age were more likely to require renal 
replacement therapy (100% vs 0%, P < .001), intensive care unit admission (75% vs 9%, 
P = .013), and a longer median length of stay (10 vs 7 days, P = .037) than were older patients. 
Renal replacement therapy consisted of peritoneal dialysis with a median duration of 5.5 days 
(range 2-23 days). Patients <5 years of age did not differ significantly from the group of children 
≥5 years of age in terms of ethnicity, NSAID dosing, sex, or body mass index percentile 
(Table III). 
 
 
Average hospital reimbursement for our 27 patients was $12 502 and average nephrologist 
reimbursement was $1398. For the patients <5 years of age, average hospital reimbursement was 
$27 157 and average nephrologist reimbursement was $2796. Patients ≥5 years of age had 
average hospital reimbursement of $9953 with average nephrologist reimbursement of $1119. 
Table III.
Comparing course and characteristics by age
Age <5 (n = 4) Age≥5 (n = 23)P  value
Male patient,  No. 2 (50%) 10 (43%) 1
White, No. 4 (100%) 20 (87%) 1
History of exceeding recommended dose<comma> No.* 0 of 1 (0%) 5 of 19 (26%) 1
Body mass index percentile† 55 (26.1-99.5) 87 (6.8-99.1) 0.417
AIN, No. 1 (25%) 5 (22%) 1
Length of stay, d‡ 10 (8-24) 7 (1-12) 0.037
Required dialysis, No. 4 (100%)  0 ()       <.001
Required intensive care unit stay<comma> No. 3 (75%) 2 (9%) 0.013
∗ Dose information unavailable for remaining 7 patients. 
† Length versus weight percentile if age <2 years. 
‡ Data reported as median (range). 
 
 
Sixteen of 23 patients with follow-up lab tests available demonstrated a return of eGFR to >90 
mL/min/1.73 m
2
 at most recent testing. Six had eGFR >60 but <90 mL/min/1.73 m
2
, and 1 
patient had an eGFR of 56 mL/min/1.73 m
2
. None had an ongoing need for renal replacement 
therapy. Median time from presentation to most recent follow-up laboratory testing available was 
272 days (range 20-2728 days). 
Diagnostic Studies 
Eleven of the 27 patients had a renal biopsy. Findings consisted of AIN with eosinophils 
consistent with acute drug reaction in 5 patients. One patient had a mixed picture of ATN and 
AIN, and 2 had ATN with focal active interstitial inflammation, consistent with drug reaction. 
One patient had acute tubulointerstitial disease, predominantly consisting of tubular necrosis. 
One patient had blebbing and loss of brush borders consistent with ATN, and another had diffuse 
ATN with a pattern of proximal tubular injury more consistent with toxic than with ischemic 
injury. 
Twenty-six patients had an abdominal ultrasound. Findings consisted of large echogenic kidneys 
consistent with medical renal disease in 8 patients, echogenicity without enlargement of kidneys 
in 5 patients, and increased kidney size alone in 3 patients. One patient had grade III 
hydronephrosis, and 1 patient had mild right hydronephrosis with increased echogenicity and an 
absent left kidney. Eight patients had normal ultrasound findings. 
99m
Tc-mercaptoacetyltriglycine (MAG3) scan was performed in 13 of the 27 patients. Findings 
consisted of normal perfusion with persistence of radiotracer in the kidneys for >50 minutes 
consistent with ATN in 7 patients. Three patients had minimal persistence of radiotracer >50 
minutes consistent with mild ATN. One patient had poor clearance of radiotracer with left 
kidney demonstrating 73% of renal mass. One patient had absent left kidney tissue and an 
enlarged right kidney with adequate perfusion and persistence of radiotracer in the kidney >4 
hours. One patient had multiple peripheral defects in the right kidney representing scarring 
versus infarcts and adequate perfusion with some retention of radiotracer >50 minutes; a 
subsequent kidney magnetic resonance angiography/imaging did not demonstrate perfusion 
defects, and on biopsy this patient was found to have interstitial nephritis. 
Discussion 
As in other recent studies, we found that AKI is most commonly associated with comorbid 
conditions and that the most common cause of AKI is multifactorial.
11 and 12
 NSAID-associated 
AKI has been previously reported in 54 infants and children through case reports or small case 
series. Ibuprofen,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24
 naproxen,
17, 20, 21, 25, 26 and 27
 ketorolac,
16, 21 and 28
 
diclofenac,
17, 27 and 29
 dipyrone,
17 and 30
 ketoprofen,
13
 flurbiprofen,
23
 sulindac,
27
 rofecoxib,
31
 and 
niflumic acid
32
 have all been reported in cases of NSAID-associated AKI, either alone or in 
combination with other NSAIDs. 
Three case series of 6-7 children with NSAID-associated AKI have been reported. Ulinski et al
13
 
report NSAID-associated AKI in 7 patients; 6 were previously healthy and 1 had a history of a 
kidney transplant. Ibuprofen was used by 6 of the patients and ketoprofen by 1. The patients all 
took NSAIDs in accordance with recommended dosing. Kause et al report 7 patients aged 13-18 
years presenting after ingestion of over-the-counter antipyretics, 6 of whom ingested NSAIDs 
(naproxen, diclofenac, dipyrone, and/or ibuprofen) and 1 who ingested an overdose of 
acetaminophen.
17
 Six patients reported vomiting or less than usual fluid intake. Three patients 
underwent kidney biopsy, with 1 showing mild interstitial inflammation. Lantz et al reported 7 
cases of AKI associated with niflumic acid intake.
32
 The medication was given in recommended 
doses in all 7 cases. Five patients reported decreased oral intake during their acute illness. Five 
were suspected based on clinical course to have AIN, and 3 of these were confirmed by kidney 
biopsy. One patient did not recover renal function and required ongoing dialysis. One patient 
recovered some renal function after 28 days but 6 months later required hemodialysis.
32 
Several other reports of NSAID-associated AKI have been reported and are summarized in 
Table IV. A total of 54 patients are represented in case reports and series from 1993 to 2009. 
Twenty-eight (53%) were reported to have decreased oral intake before admission, 38 (70%) 
used the NSAID for ≤1 week, and 30 of 50 for which data were reported (60%) took normal 
recommended NSAID doses. 
Our study is the largest series to date demonstrating that NSAIDs are a common cause of AKI in 
children. During an 11.5-year period, NSAID use accounted for 2.7% of episodes of AKI at our 
institution. However, it should be noted that in our population, many patients who were deemed 
to have developed multifactorial AKI (and thus were not included in the case definition of 
NSAID-associated AKI) did have NSAID exposure as one of their multiple risk factors for AKI. 
Furthermore, many patients in our excluded population developed AKI as a complication of 
inpatient therapy for an unrelated primary illness or condition. Therefore, we may have 
underestimated the role of NSAIDs as an etiology of AKI in children. Interestingly, NSAID-
associated AKI typically occurred in children who had ingested NSAIDs at the recommended 
dose. 
There may be a trend toward more severe AKI based on eGFR nadir in patients who reported 
volume depletion, although that did not reach statistical significance. Volume depletion has been 
previously reported to be a factor in development of NSAID-associated AKI.
1, 3, 13, 17, 29 and 32
 
There was no statistically significant difference in eGFR nadir in patients taking more than the 
recommended dose of NSAIDs compared with those with normal dosing. 
Surprisingly, we found that younger children with NSAID-associated AKI may have more 
severe disease than older children. The reason for this finding is unknown but could be due to an 
increased susceptibility to the toxic renal effects of NSAIDs. 
The cost of care by physicians is markedly underrepresented in our calculation, as billing data 
from intensive care specialists, renal pathologists, pediatric surgeons, and other consultants were 
not available to be included. During 11.5 years of study, a minimum total of $375 293 was spent 
at our institution on the care of patients with NSAID-associated AKI. This represents a 
significant cost, especially when considering that NSAID-associated AKI is avoidable. Further 
contributing to the health care cost burden in these patients is the cost of chronic kidney disease 
management. Only 16 of the 23 patients (70%) for whom follow-up lab results were available 
returned to an eGFR of >90 mL/min/1.73 m
2
, suggesting an increased risk of progressive chronic 
kidney disease, with its associated costs and complications. 
 Table IV.
Reports of NSAID-
associated AKI in the 
literature
Author (reference) No. of 
patients
Decrease
d oral 
intake
NSAID used Duration of 
use
Recommended 
dosage used
Age, y Peak 
creatinine,  
mg/dL
Recovery time 
(creatinine 
normalized)
Ulinksi et al13 7 5 of 7 Ibuprofen: 6 1-5 d 7 of 7 13 (4-15) 3.2 (1.9-7.3) 7 d (median)
Ketoprofen: 1
Lantz et al32 7 4 of 7 Niflumic acid: 7 1-5 d (3-14 d 
before 
admission)
7 of 7 0.9-12 1.7-9 4-28 d: 5 
patients
Ongoing 
impairment: 2 
patients
Krause et al17 7 (6 
w/NSAID)
6 of 7 Dipyrone: 2 1-4 d 6 of 7 13-17.5 1.7-8.3 7-16 d
Ibuprofen: 1 
Naproxen/diclofenac: 1
Dipyrone/diclofenac: 1
Ibuprofen/naproxen: 1
Ibuprofen/dipyrone: 1
1 No Zafanello et al14 2 d Yes: 5 
mg/kg/dose
5 6.34 32 d
Moghal et al15 1 Yes Ibuprofen 7 d (6 doses) Yes: 5 
mg/kg/dose
1.5 5.9 Ongoing 
impairment
Kallangdowar et al16 2 1 of 2 Ketorolac 2-3 d 2 of 2 0.75; 12 2.2; 6.3 4; 12 d
Wong et al18 1 Yes Ibuprofen 2 d Yes: 5 
mg/kg/dose
0.75 2.4 21 d
Del Vecchio and 
Sundel19
1 No Ibuprofen 2 d No data 1.2 3.4 9 d
Schaller and Kaplan20 4 0 of 4 Ibuprofen/naproxen: 1 1-4 d 3 of 4 3.5-19 1.7-6 7-90 d
Naproxen: 1
Ibuprofen: 2
Nakahura et al21 3 1 of 3 Ibuprofen: 1 3-270 d No data 13-17 2.2-2.6 <1 y: 1 patient
Toradol: 1 Ongoing 
impairment: 2 
patients
Naproxen: 1
Wattad et al22 1 Yes Ibuprofen 1 d (2 wk 
before 
admission)
Yes 14 4.7 21 d
McIntire et al23 2 1 of 2 Flurbiprofen: 1 4-8 d 0 of 2 14-Dec 2.3-5.2 10 d: 1 patient
Ibuprofen: 1 No data: 1 
patient
Kim et al24 1 No Ibuprofen 1x— only No 2 2.1 3 d
Kovacevic et al25 1 Yes Naproxen 4 d (1 wk 
before 
admission)
No 17 4 90 d
Becker-Cohen and 
Frishberg26
2 No Naproxen: 1 2-30 d 2 of 2 10 6.3 10 d
Diclofenac: 1
Kulling et al27 3 0 of 3 Sulidinac: 2 1x— only No 14-19 2.1-2.3 14 d: 1 patient
Naproxen: 1 No data: 2 
patients
Buck and Norwood28 1 Yes Ketorolac 3 d Yes 17 8.4 14 d
Matthews-John et al29 4 4 of 4 Diclofenac: 3 2-180 d 4 of 4 14-Jul 1.7-7.1 3-5 d: 3 patients
Ibuprofen/diclofenac/indometha
cin: 1
Ongoing 
impairment: 1 
patient
Abu-Kishk et al30 3 No data Dipyrone: 3 1x— only No 14-17 2.5-4.9 10-12 d
Fletcher et al31 3 1 of 3 Rofecoxib: 3 1-3 d 2 of 3 1.5-14 1.9-3.3 6-28 d
These concerns lead into the question of whether renal functions should be obtained as per 
routine before the administration of NSAIDs. In the outpatient setting, this would not be feasible, 
but with increasing recognition of NSAIDs as a cause of AKI and the pathophysiologic 
understanding of NSAID-associated AKI, ascertainment of renal function may be indicated 
before NSAID administration to inpatients. 
Because this is a retrospective study, we are limited in our ability to draw conclusions regarding 
timing of onset of AKI with respect to timing of NSAID exposure. Also, the majority of children 
in our study were previously healthy, so very few had serum creatinine values determined before 
they presented with AKI. Finally, because many of the patients presented with an acute illness 
causing dehydration, it is possible that some patients would have experienced AKI even had they 
not been exposed to NSAIDs. However, given the proposed mechanism of NSAID-associated 
AKI, it is likely that NSAID use played an important role. 
Appendix 
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